HENGRUI PHARMA (01276) · Company profile · Eqvero

HENGRUI PHARMA

01276HKEX

Unit: CNY	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	28.01 bn CNY	25.01 bn CNY	22.38 bn CNY	21.21 bn CNY	25.78 bn CNY
Cost of revenue	3.54 bn CNY	3.1 bn CNY	2.86 bn CNY	2.93 bn CNY	3.24 bn CNY
Research and development expense	6.96 bn CNY	6.58 bn CNY	4.95 bn CNY	4.89 bn CNY	5.94 bn CNY
Selling, general and administrative expense	11.91 bn CNY	10.89 bn CNY	9.99 bn CNY	9.65 bn CNY	12.24 bn CNY
Operating profit after depreciation	8.09 bn CNY	6.48 bn CNY	4.18 bn CNY	3.01 bn CNY	3.78 bn CNY
Operating profit before depreciation	8.93 bn CNY	7.25 bn CNY	4.88 bn CNY	3.59 bn CNY	4.3 bn CNY
EBIT	8.09 bn CNY	6.48 bn CNY	4.18 bn CNY	3.01 bn CNY	3.78 bn CNY
EBITDA	8.93 bn CNY	7.25 bn CNY	4.88 bn CNY	3.59 bn CNY	4.3 bn CNY
Interest expense	14.35 m CNY	5.56 m CNY	5.9 m CNY	6.49 m CNY	4.71 m CNY
Profit before tax	8.71 bn CNY	7.17 bn CNY	4.67 bn CNY	3.97 bn CNY	4.47 bn CNY
Income tax expense	990.62 m CNY	832.7 m CNY	389.29 m CNY	153.42 m CNY	-17.72 m CNY
Income before extraordinary items	7.71 bn CNY	6.34 bn CNY	4.3 bn CNY	3.91 bn CNY	4.53 bn CNY
Common dividends	—	1.28 bn CNY	1.27 bn CNY	1.02 bn CNY	1.02 bn CNY
Total dividends	—	1.28 bn CNY	1.27 bn CNY	1.02 bn CNY	1.02 bn CNY

Quotes are end-of-day data. Content is for research purposes and is not investment advice.